← Product Code [HCG](/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/HCG) · K073419 # PVA PLUS VIAL PVA FOAM EMBOLIZATION PARTICLES, PVA PLUS CONVENIENCE KIT PVA EMBOLIZATION PARTICLES (K073419) _Rj Medical, Inc. · HCG · Feb 14, 2008 · Neurology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/HCG/K073419 ## Device Facts - **Applicant:** Rj Medical, Inc. - **Product Code:** [HCG](/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/HCG.md) - **Decision Date:** Feb 14, 2008 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 882.5950 - **Device Class:** Class 2 - **Review Panel:** Neurology - **Attributes:** Therapeutic ## Indications for Use PVA particles may be used for vascular occlusion of blood vessels within the neurovascular systems. They are intended for use in the endovascular management of arteriovenous malformations (AVM's) and neoplastic lesions when presurgical devascularization is desirable. ## Device Story Nonabsorbable synthetic polyvinyl alcohol (PVA) foam particles; uncoated; no colorants/additives. Delivered via syringe through infusion catheter to target anatomical site. Used in neurovascular system for vascular occlusion; indicated for AVMs and neoplastic lesions requiring presurgical devascularization. Operated by clinicians in endovascular procedures. Device provides mechanical occlusion of blood vessels to reduce blood flow to target lesions, facilitating surgical intervention. Provided sterile, non-pyrogenic, single-use. ## Clinical Evidence No clinical data. ## Technological Characteristics Nonabsorbable synthetic polyvinyl alcohol (PVA) foam particles. Uncoated, no additives. Available in various particle sizes. Sterile, non-pyrogenic, single-use. Mechanical occlusion principle. ## Regulatory Identification A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral ateriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in other vascular applications are also not included in this classification, see § 870.3300. ## Special Controls *Classification.* Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 882.1(e). ## Predicate Devices - PVA PLUS Foam Embolization Particles ([K001678](/device/K001678.md)) - MaxiStat PVA Foam Embolization Particles ([K020033](/device/K020033.md)) - MicroStat PVA Foam Embolization Particles ([K032619](/device/K032619.md)) - Modified PVA PLUS, Modified MaxiStat, and Modified MicroStat PVA Foam Embolization Particles ([K053548](/device/K053548.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K073419 1/3 110 | 4 #### 5.0 510(k) SUMMARY In accordance with Title 21 of the Code of Federal Regulations Part 807 (21 CFR section 807), and in particular section 807.92, the following summary of safety and effectiveness information is provided: #### 5.1 Submitted By: RJ Medical, Inc. 4921 Robert J. Mathews Pkwy., #2 El Dorado Hills, CA 95762 Telephone: 1(916)941-6913 Contact: Jim Innes President Date Prepared: # December 3, 2007 #### 5.2 Device Name: Trade or Proprietary Names: PVA PLUS" Vial PVA Foam Embolization Particles PVA PLUS" Convenience Kit PVA Foam Embolization Particles MicroStat" Convenience Kit PVA Foam Embolization Particles MaxiStat" Convenience Kit PVA Foam Embolization Particles Common or Usual Name: Classification Name: particles Polyvinyl alcohol (PVA) foam embolization Neurovascular embolization device #### 5.3 Predicate Devices The subject devices are substantially equivalent to the following predicate devices: - * PVA PLUS" Foam Embolization Particles (Surgica Corp.; K001678) - * MaxiStat" PVA Foam Embolization Particles (Surgica Corp .; K020033) - * MicroStat" PVA Foam Embolization Particles (Surgica Corp.; K032619) {1}------------------------------------------------ K073419 3/2 - · Modified PVA PLUS™, Modified MaxiStat™, and Modified MicroStat™ PVA Foam Embolization Particles (Protein Polymer Technologies, Inc .; K053548) #### 5.4 Device Description The subject devices are particles of nonabsorbable synthetic polyvinyl alcohol (PVA) foam. The devices do not contain any colorant or other additive, and are uncoated. Each is offered in a range of particle sizes, from which the clinician may select the particle size most appropriate for the desired effect and targeted vasculature. The devices are intended to be delivered to the selected anatomical site by means of a syringe through an infusion catheter of appropriate diameter. The devices are provided sterile, non-pyrogenic, and are intended for single use. #### ર્સ્ટ Intended Use PVA particles may be used for vascular occlusion of blood vessels within the neurovascular systems. They are intended for use in the endovascular management of arteriovenous malformations (AVM's) and neoplastic lesions when presurgical devascularization is desirable. #### ર્ડ.6 Comparison to Predicate Devices The subject devices are identical to both the Surgica product (K001678) PVA Foam Embolization Particles and the Corporation Protein Polymer Technologies, Inc. product (K053548) Modified PVA PLUS™, Modified MaxiStat™, and Modified MicroStat™ PVA Foam Embolization Particles. Surgica Corporation was the exclusive developer and only manufacturer of all of these products. Surgica Corporation recently sold all of the assets, including Patents, Trademarks, Fixtures, Quality Systems, Procedures, Specifications, etc. to RJ Medical. Former Surgica management has transferred everything to RJ Medical, including training, to resume manufacturing and distribution of the devices. The only changes to the products are the manufacturer and the distributor identifications. Names on the labeling will reflect these items. #### 5.7 Summary of Non-Clinical Tests (Not Applicable) {2}------------------------------------------------ ## 5.8 Summary of Clinical Tests (Not Applicable) ### 5.9 Conclusions of Non-Clinical and Clinical Tests (Not Applicable) : : {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. In the center of the seal is an abstract symbol that resembles an eagle or bird with outstretched wings. The symbol is composed of three curved lines that converge at the center and then extend outward. FEB 14 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 RJ Medical, Inc. % Mr. Jim Innes President 4921 Robert J. Mathews Parkway #2 El Dorado Hills, California 95762 Re: K073419 Trade/Device Name: PVA PLUSTM Vial PVA Foam Embolization Particles PVA PLUSTM Convenience Kit PVA Foam Embolization Particles MicroStat™ Convenience Kit PVA Foam Embolization Particles MaxiStat™ Convenience Kit PVA Foam Embolization Particles Regulation Number: 21 CFR 882.5950 Regulation Name: Neurovascular embolization device Regulatory Class: II Product Code: HCG Dated: December 3, 2007 Received: December 5, 2007 Dear Mr. Innes: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must {4}------------------------------------------------ ## Page 2 - Mr. Jim Innes comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely vours. Mark N. Millerson Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ RJ Medical, Inc. # Indications for Use 510(k) Number (if known): _________________ Devicc Names: PVA PLUS™ Vial PVA Foam Embolization Particles PVA PLUS™ Convenience Kit PVA Foam Embolization Particles MicroStat™ Convenience Kit PVA Foam Embolization Particles MaxiStat™ Convenience Kit PVA Foam Embolization Particles Indications for Use: PVA particles may be used for vascular occlusion of blood vessels within the neurovascular systems. They are intended for use in the endovascular management of arteriovenous malformations (AVM's) and neoplastic lessions when presurgical devascularization is desirable. | Prescription Use (Part 21 CFR 801 Subpart D) | X | AND/OR | Over-The-Counter Use (21 CFR 801 Subpart C) | |----------------------------------------------|---|--------|---------------------------------------------| |----------------------------------------------|---|--------|---------------------------------------------| (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-On) Division of General, Restorative, and Neurological Devices | 510(k) Number | 2073419 | |---------------|---------| |---------------|---------| --- **Source:** [https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/HCG/K073419](https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/HCG/K073419) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com